{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T04:24:33Z","timestamp":1729830273612,"version":"3.28.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1715","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The injectable interleukin (IL)-23 antagonist risankizumab-rzza (Skyrizi \u2013 Abbvie), previously approved by the FDA for treatment of Crohn\u2019s disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is also approved for treatment of plaque psoriasis and psoriatic arthritis.<\/jats:p>","DOI":"10.58347\/tml.2024.1715d","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T19:22:58Z","timestamp":1729797778000},"page":"182-184","source":"Crossref","is-referenced-by-count":0,"title":["Risankizumab (Skyrizi) for Ulcerative Colitis"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,11,11]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T19:22:58Z","timestamp":1729797778000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1715d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":0,"journal-issue":{"issue":"1715","published-online":{"date-parts":[[2024,11,11]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1715d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}